REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 212 filers reported holding REATA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $1,430,000 | -74.8% | 54,226 | -3.9% | 0.00% | -75.0% |
| Q3 2021 | $5,680,000 | -28.9% | 56,455 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $7,990,000 | -11.9% | 56,455 | -37.9% | 0.01% | -14.3% |
| Q1 2021 | $9,065,000 | +42.6% | 90,923 | +76.8% | 0.01% | +40.0% |
| Q4 2020 | $6,358,000 | +29.3% | 51,431 | +1.9% | 0.01% | +25.0% |
| Q3 2020 | $4,918,000 | -40.6% | 50,484 | -4.9% | 0.00% | -50.0% |
| Q2 2020 | $8,282,000 | +13.5% | 53,081 | +5.0% | 0.01% | -11.1% |
| Q1 2020 | $7,300,000 | -49.4% | 50,577 | -28.3% | 0.01% | -30.8% |
| Q4 2019 | $14,422,000 | +384.0% | 70,547 | +90.1% | 0.01% | +333.3% |
| Q3 2019 | $2,980,000 | -3.5% | 37,119 | +13.4% | 0.00% | -25.0% |
| Q2 2019 | $3,089,000 | +9.5% | 32,735 | -0.8% | 0.00% | +33.3% |
| Q1 2019 | $2,821,000 | +76.4% | 33,001 | +15.8% | 0.00% | +50.0% |
| Q4 2018 | $1,599,000 | +459.1% | 28,503 | +713.7% | 0.00% | – |
| Q3 2018 | $286,000 | – | 3,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |